Anti-mucositis gel developed at UGR to be widely available by 2022
Researchers from the University of Granada have developed new medication which could help to treat and prevent chemotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients. The melatonin compound, in the form of a gel, has now passed phases 1 and 2 of clinical trials and is expected to be on sale by 2022.